Zolendronic acid (Zometa) therapy is considered medically necessary in patients who experience pain from bone metastasis of breast cancer, lung cancer neuroendocrine tumors, prostate cancer, thyroid cancer and other types of solid tumors, hypercalcemia secondary to malignancy, multiple myeloma, including latent multiple myeloma and solitary plasmacytoma, Secondary prophylaxis of drug-induced osteopenia to prostate cancer on androgen deprivation therapy. The following indication is Off label indication, following ASCO guidelines: Systemic Mastocytosis
Zolendronic acid (Reclast) therapy is considered medically necessary in patient for the treatment and prevention of postmenopausal osteoporosis, treatment to increase bone mass in men with osteoporosis, treatment and prevention of glucocorticoid-induced osteoporosis, treatment of Paget’s disease of bone in men and women
Contraindications:
Hypocalcemia
Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment
Hypersensitivity to any component of Reclast or Zometa
